

THE CLOT SPOT

THE ANTICOAGULATION SERVICE NEWSLETTER FROM HHFT

CONTENTS

REDUCING ADMISSIONS THROUGH INR MONITORING


01

PATIENT SURVEY

02

CLINICAL TRIALS

02



REDUCING ADMISSIONS THROUGH INR MONITORING

As we all know, maintaining patients on warfarin in their target range is all about walking the tightrope between high INRs and associated bleeding risk, and low INRs and associated thrombotic risk.


In the HHFT Anticoagulation team we aim to reduce hospital admissions for high INRs unless absolutely necessary by omitting doses of warfarin, and only giving vitamin K if clinically indicated.

But what is the scale of the problem? We gather data on a monthly basis to see how many dose instructions we provide every month, and how many of the INRs are above 5, and above 8.


We are actively targeting patients with poor Time in Therapeutic Range (TTR) and prompting GPs to review the patient's anticoagulation where we feel it is appropriate for them to switch to a DOAC, or consider if formal anticoagulation is still appropriate.

Recent benchmarking data for HHFT indicates that our overall TTR is 75% which is above the national average of 65% and shows the Anticoagulation team's endeavours to ensure every patient is on the most appropriate and effective oral anticoagulant. Nurse counselling sessions aim to ensure patients are informed of the risks and benefits of anticoagulation with associated adherence to their treatment plan.

Quality of our Dosing



Quantity of our Dosing



PATIENT SURVEY

Earlier this year one of the Anticoagulation Nurses designed a satisfaction survey, which was distributed to both patients that attended a face to face appointment, and patients that were on warfarin and used our postal service. There was a good response (60%), and by and large the feedback was very positive. There was some useful feedback to help improve our service.

We asked: How accessible do you find the location of the clinic?

Patients said: "Everything excellent except signposting to the (Winchester) clinic"

We have ordered new signage to help patients find us.

We asked: How happy are you with the way the telephone enquiries are dealt with by the centre?

Patients said: "Could not get through"
"Sometimes no-one is available so leaving a message usually suffices"

"Staff at Winchester are very good and answer phone calls very quickly. Very pleased with this service"

We asked: How satisfied are you with the anticoagulation clinic opening times?

Patients said: "For any queries I have, I pop into the clinic and manage to speak to a nurse."

We asked: Did the staff discuss your care in a way that you found easy to understand?

Patients said: "Friendly and professional. Kind and explained everything very clearly"
"The nurse was very helpful and answered all my questions and concerns. I'm leaving feeling much better than when I came in."

"I found the consultation very relaxed and extremely informative. The nurse was very kind and knowledgeable. She took the time to answer all my questions."

WHAT WE'RE DOING OR HAVE DONE ALREADY TO ADDRESS THE FEEDBACK

- Phone lines are busy but there are two numbers, both with answerphone facility. (BNHH - 01256 313415 and RHCH - 01962 824126) Patients can also contact us by email at bnh-ft.anticoagclinic.nhs.net
- New signage has been ordered for the Winchester Anticoagulation clinic.
- Patients are offered appointments at either Winchester or Basingstoke hospitals.
- INRs should arrive within 5 working days. Patients are encouraged to call us if the INR report is not received within a week.
- We are researching online alternative methods for sending you your INR results.

CLINICAL TRIALS

The department have a number of on-going clinical trials that patients can sign up to. Please see a list of our studies below or contact the team for further details.

- **FIRST**- A non-commercial observational study in Rivaroxaban, to study the incidence of long term complications (VTE, PTS and CTEPH) for VTE patients treated with Rivaroxaban.
- **RE-COVERY DVT/PE**: A commercial observational global study on treatment and secondary prevention of acute venous thromboembolism
- **ETNA VTE**: A commercial observational study on Edoxaban treatment in routine clinical practice in patients with Venous Thromboembolism in Europe
- **EMIT-AF/VTE**: A commercial observational study on Edoxaban management in diagnostic and therapeutic procedures
- **PEP-WARF**: A non-commercial observational study developing dosing algorithms in patients with extreme phenotypes who require anticoagulation with warfarin

CONTACT US



Opening Hours Monday to Friday, 9am to 5pm



BNHH Centre Reception - 01256 314793
BNHH Centre Fax - 01256 314889
Anticoagulation Nurses BNHH - 01256 313415
Anticoagulation Nurses RHCH - 01962 824126



Email: bnh-ft.anticoagclinic.nhs.net